Abstract
Get full access to this article
View all access options for this article.
References
1.
Pfizer lists separately the Lyrica revenues generated in all of Europe, Russia, Turkey, Israel, and Central Asia countries ($347 million in 2018, $553 million in 2017). Those revenues are listed by Pfizer's “Essential Health” operating segment, while its “Innovative Health” segment records Lyrica revenues generated elsewhere in the world, including the U.S. ($4.622 billion in 2018, $4.511 billion in 2017).
2.
Biogen receives a share of U.S. pre-tax profits on sales of Rituxan, which is marketed by Genentech (Roche). Sales figures do not include U.S. pre-tax profits generated by Biogen, since the company only discloses those profits combined with profits from Gazyva® (obinutuzumab), and does not break out each product separately. Biogen reported combined Rituxan-Gazyva pre-tax profits of $1.432 billion for 2018, and $1.316 billion for 2017.
3.
Pfizer markets Enbrel outside the U.S. and Canada, where the treatment is marketed by Amgen.
4.
Pfizer figures for Eliquis consist of “alliance revenues” reflecting products co-developed with partner companies, as well as direct sales in some regions of the world.